|
|
 |
|
Viewing report
|
|
 |
 |
Anti-Counterfeiting Strategies - Combating Fake Pharmaceuticals
Datamonitor, Dec 2007, Pages: 115
CHAPTER 1 EXECUTIVE SUMMARY 4 Scope of the report 4 Chapter summary 4 Key findings 5 CHAPTER 2 COUNTERFEITING - THE SCALE OF THE PROBLEM 9 Pharmaceutical counterfeiting - a growing global problem 10 What is a counterfeit medicine? 10 Counterfeit medicines are on the increase 12 Counterfeits with no APIs predominate 13 What type of drugs are counterfeited - lifestyle versus lifesaving? 13 Counterfeit pharmaceuticals - a problem for both rich and poor nations 15 The cost of counterfeit medicines 16 The economic cost of counterfeiting 16 The health cost of counterfeiting 17 The governmental cost of counterfeiting 18 Sources of counterfeit medicines 19 Factors enabling and driving the production and distribution of counterfeit medicines 21 How counterfeit medicines reach the market 23 Parallel trade provides a point of entry for counterfeit medicines 24 The role of the internet in counterfeiting 27 CHAPTER 3 ANTI-COUNTERFEITING STRATEGIES 31 Anti-counterfeiting strategies 32 Internal anti-counterfeiting business units and policies 33 Secured supply chains 35 Simplifying the supply chain 36 FDAs prescription drug pedigree requirements 38 The emergence of e-pedigrees 41 Use of cutting edge anti-counterfeiting technologies 43 Preventative technologies 45 Unit-of-use packaging 46 Tamper-evident packaging 46 Authentication technologies 47 Overt technologies 50 Covert technologies 54 Forensic technologies 56 Diagnostic anti-counterfeiting strategies 58 Serialization and track & trace technologies 60 RFID 62 2D-barcodes are favored by EFPIA 69 Which to adopt, RFID or 2D-barcodes? 73 Improving legislation, regulation and law enforcement 78 Inadequate regulation, legislation and enforcement promotes counterfeiting 79 What will be the impact of IMPACT? 82 Summary of national and international anti-counterfeiting initiatives 87 Enhancing law enforcement 88 Education of consumers 93 National and international education initiatives 94 Industry-supported patient education 96 CHAPTER 4 BIBLIOGRAPHY 98 Our reports 98 Websites 98 Publications, online articles and meetings 109 Glossary of terms 111 List of Tables Table 1: Countries with IP concerns to the US - Priority watch list, 2007 20 Table 2: Examples of tamper evident solutions 47 Table 3: Benefits of using different authentication measures throughout the pharmaceutical supply chain 49 Table 4: Overt anti-counterfeiting technologies 51 Table 5: Covert anti-counterfeiting technologies 55 Table 6: Forensic anti-counterfeiting technologies 56 Table 7: Readability of covert/forensic anti-counterfeit technologies 57 Table 8: Serialization/track & trace anti-counterfeiting technologies 61 Table 9: Comparison of RFID and 2D-barcode technologies 74 Table 10: Pros and cons of 2D-barcode, RFID and hybrid strategies 77 Table 11: California Express Solutions Team - project roles and responsibilities to harmonize e-pedigree, serialization and authentication 78 List of Figures Figure 1: Defining counterfeit, substandard, diverted and genuine medicines 11 Figure 2: Counterfeit medicines are on the rise 12 Figure 3: Different types of counterfeit drugs that have been reported, 2000-01 13 Figure 4: Global incidence of counterfeiting, diversion and pharmaceutical theft, 2004-05 14 Figure 5: Number of incidents and seizures of counterfeit medicines by country, 2005 20 Figure 6: Factors enabling and driving the production and distribution of counterfeit medicines 21 Figure 7: Routes of entry for counterfeit medicines in the supply chain 24 Figure 8: Anti-counterfeiting strategies that should be employed throughout the manufacturing and distribution of medicines 32 Figure 9: AstraZenecas anti-counterfeiting efforts in the US 34 Figure 10: Distributor Licensing and Pedigree Requirements by State, October 2007 40 Figure 11: SupplyScapes timeline for meeting the 2009 California deadline 42 Figure 12: Types of anti-counterfeiting strategies 44 Figure 13: The use of bar coding was the most popular anti-counterfeit strategy employed by surveyed pharmaceutical manufacturers, 2005 45 Figure 14: How EPC and RFID work 63 Figure 15: Pfizers risk-based approach to track & trace, authentication and pedigree technologies 76 Figure 16: The Declaration of Rome - February 2006 82 Figure 17: Survey findings for the most suitable methods of preventing counterfeit medicines, 2007 85 Figure 18: Anti-counterfeiting strategies that should be employed throughout the manufacturing and distribution of medicines 93 Figure 19: Pfizer educates patients on the threat of counterfeit medicines 96
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Pharmaceutical Anti-Counterfeiting Strategies
Prescription Drug Counterfeiting
Pharmaceutical Counterfeiting in the EU: Where Are We Now?
The Global Report on Counterfeiting: Anti-counterfeiting and the Apparel Industry
Strategic Analysis of the North American Automotive Parts Counterfeiting and Gray Market
Global losses in pounds sterling due to counterfeiting and forgery, counterfeit retail goods, pirated software, pirated compact disks and cassettes, and from unlicensed medicines for 2000
Apparel Counterfeiting in China - Management Briefing
Business and Legal Strategies in Trademark Anti-Counterfeiting Enforcement: ReedLogic Video Seminar with Raymond R. Castello of Fish & Richardson P.C.
Chinese White-box and Counterfeit Netbook PCs: Current Status and Future Industry Impact
Counterfeit Car Parts in the Global Auto Industry
Low-Cost RFID Smart Labels - International Markets & Opportunities in Europe & North America
Analysis on Anti-cold Medicines in Recent Three Years
|
 |
|
|